Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date

Revue de Medecine Veterinaire

Volumn 167, Issue 7-8, 2016, Pages 192-200

  Karayannopoulou, M ^a   Lafioniatis, S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anticancer agents; Chemotherapy; Dog; Mammary cancer; Systemic therapy

Indexed keywords

EID: 84979662821     PISSN: 00351555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. ADVANI P., CORNELL L., CHUMSRI S., MORENOASPITIA A.: Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy, 2015, 7, 321-335. http://dx.doi.org/10.2147/BCTT. S90627
2. ALKAN F. U., ANLAS C., CINAR S., YILDIRIM F., USTUNER O., BAKIREL T., GUREL A.: Effects of curcumin in combination with cyclophosphamide on canine mammary tumour cell lines. Vet. Med.-Czech., 2014, 59, 553-572.
3. ANKUR S., DHAKATE M. S., UPADHYE S. V.: Chemotherapeutic management of canine mammary tumours. Vetscan., 2010, 5, article 55. http://www.vetscan. co.in/v5n1/chemotheraputic-management-of-canine-mammary-tumors.htm
4. BREAST CANCER [Internet]: American Cancer Society, Atlanta, Georgia [updated 2014 Sept 25, cited 2015 Jul. 7]. Available from: http://www.cancer.org/cancer/breastcancer/detailedguide
5. CARVALHO M. I., GUIMARAES M. J., PIRES I., PRADA J., SILVA-CARVALHO R., LOPES C., QUEIROGA F. L.: EGFR and microvessel density in canine malignant mammary tumours. Res. Vet. Sci., 2013, 95, 1094-1099.
6. CHEMOTHERAPY FOR BREAST CANCER [Internet]: American Cancer Society, Atlanta, Georgia [updated 2014 Sept 25, cited 2015 Jul. 7]. Available from: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-chemotherapy
7. CLEMENTE M., DE ANDRÉS P. J., PEÑA L., PÉREZ-ALENZA M. D.: Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy. Vet. Rec., 2009, 165, 78-81.
8. DE M SOUZA C. H., TOLEDO-PIZA E., AMORIN R., BARBOZA A., TOBIAS K. M.: Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can. Vet. J., 2009, 50, 506-510.
9. DORLO T. P. C., BALASEGARAM M., BEIJNEN J. H., DE VRIES P. J.: Miltefosin: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J. Antimicrob. Chemother., 2012, 67, 2576-2597.
10. DUIJSINGS D., HOUWELING M., VAANDRAGER A. B., MOL J. A., TEERDS K. J.: Hexadecylphosphocholine causes rapid cell death in canine mammary tumour cells. Eur. J. Pharmacol., 2004, 502, 185-193.
11. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 2005, 365, 1687-1717.
12. GUIL-LUNA S., SÁNCHEZ-CÉSPEDES R., MILLÁN Y., DE ANDRÉS F. J., ROLLÓN E., DOMINGO V., GUSCETTI F., MARTÍN DE LAS MULAS J.: Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas. J. Vet. Intern. Med., 2011, 25, 518-523.
13. GULTIKEN N., GUVENC T., KAYA D., AGAOGLU A. R., AY S. S., KUCUKASLAN I., EMRE B., FINDIK M., SCHÄFER-SOMI S., ASLAN S.: Tarantula cubensis extract alters the degree of apoptosis and mitosis in canine mammary adenocarcinomas. J. Vet. Sci., 2015, 16, 213-219. http://dx.doi.org/10.4142/jvs.2015.16.2.213
14. GUSTAFSON D. L., PAGE R. L.: Cancer chemotherapy. In: S. J. WITHROW, D. M. VAIL, R. L. PAGE (éd): Withrow & MacEwen's Small Animal Clinical Oncology, 5th edn, Saunders Elsevier, St. Louis, Missouri, 2013, 157-179.
15. HENRY C. J.: Mammary cancer. In: J. D. BONAGURA, D. C. TWEDT (éd): Kirk, s Current Veterinary Therapy XV. Saunders Elsevier, St. Louis, Missouri, 2014, 375-380.
16. HERMO G. A., TORRES P., RIPOLL G. V., SCURSONI A. M., GOMEZ D. E., ALONSO D. F., GOBELLO C.: Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. Vet. J., 2008, 178, 103-108.
17. HERMO G. A., TURIC E., ANGELICO D., SCURSONI A. M., GOMEZ D. E., GOBELLO C., ALONSO D. F.: Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade. J. A. A. H. A., 2011, 47, 21-27.
18. KARAYANNOPOULOU M., KALDRYMIDOU E., CONSTANTINIDIS T. C., DESSIRIS A.: Adjuvant post-operative chemotherapy in bitches with mammary cancer. J. Vet. Med. A, 2001, 48, 85-96.
19. KHANNA C., ROSENBERG M., VAIL D. M.: A review of paclitaxel and novel formulations including those suitable for use in dogs. J. Vet. Intern. Med., 2015, 29, 1006-1012. DOI: 10.1111/jvim.12596
20. KNOTTENBELT C., CHAMBERS G., GAULT E., ARGYLE D. J.: The in vitro effects of piroxicam and meloxicam on canine cell lines. J. Small Anim. Pract., 2006, 47, 14-20.
21. KRISTIANSEN V. M., DEWI S., HORSBERG T. E., JONASDOTTIR T. J., MOE L., BERLINGER B., LINDKÆR-JENSEN S., LARSEN S.: Tolerability and pharmacokinetic profile of a novel benzene-polycarboxylic acids complex with cis-diammineplatinum (II) dichloride in dogs with malignant mammary tumours. Vet. Comp. Oncol., 2015, DOI: 10.1111/vco.12144
22. LAVALLE G. E., BERTAGNOLLI A. C., TAVARES W. L. F., CASSALI G. D.: Cox-2 expression in canine mammary carcinomas: Correlation with angiogenesis and overall survival. Vet. Pathol., 2009, 46, 1275-1280.
23. LAVALLE G. E., DE CAMPOS C. B., BERTAGNOLLI A. C., CASSALI G. D.: Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors. In Vivo, 2012, 26, 375-379.
24. LOPES J. R., MASCHIO L. B., JARDIM-PERASSI B. V., MOSCHETTA M. G., FERREIRA L. C., MARTINS G. R., GELALETI G. B., ZUCCARI D. A. P. D.: Evaluation of melatonin treatment in primary culture of canine mammary tumours. Oncol. Rep., 2015, 33, 311-319, DOI: 10.3892/or.2014.3596
25. MACASKILL E. J., DIXON J. M.: Neoadjuvant use of endocrine therapy in breast cancer. Breast J., 2007, 13, 243-250.
26. MACPHAIL C. M.: Surgery of the reproductive and genital system. In: T. W. FOSSUM (éd.): Small Animal Surgery, 4th edn, Mosby Elsevier, St. Louis, Missouri, 2013, 780-855.
27. MAJCHRZAK K., LO RE D., GAJEWSKA M., BULKOWSKA M., HOMA A., PAWLOWSKI K., MOTYL T., MURPHY P. V., KRÓL M.: Migrastatin analogues inhibit canine mammary cancer cell migration and invasion. PLoS One, 2013, 8, e76789, DOI: 10.1371/journal.pone.0076789
28. MARCONATO L., LORENZO R. M., ABRAMO F., RATTO A., ZINI E.: Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet. Comp. Oncol., 2008, 6, 90-101.
29. MATOS A. J. F., BAPTISTA C. S., GÄRTNER M. F., RUTTEMAN G. R.: Prognostic studies of canine and feline mammary tumours: The need for standardized procedures. Vet. J., 2012, 193, 24-31.
30. PAPAZOGLOU L. G., BASDANI E., RABIDI S., PATSIKAS M. N., KARAYANNOPOULOU M.: Current surgical options for mammary tumour removal in dogs. J. Veter. Sci. Med., 2014, 2, 6. http://www.avensonline.org/fulltextarticles/jvsm-2325-4645-02-0007.html
31. POIRIER V. J., HERSHEY A. E., BURGESS K. E., PHILLIPS B., TUREK M. M., FORREST L. J., BEAVER L., VAIL D. M.: Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumours. J. Vet. Intern. Med., 2004, 18, 219-222.
32. QUEIROGA F. L., RAPOSO T., CARVALHO M. I., PRADA J., PIRES I.: Canine mammary tumours as a model to study human breast cancer: Most recent findings. In Vivo, 2011, 25, 455-465.
33. ROSENTHAL R. C.: Chemotherapy. In: S. J. ETTINGER, E. C. FELDMAN (éd): Textbook of Veterinary Internal Medicine, 4th edn, W. B. Saunders Company, Philadelphia, 1995, 473-484.
34. SAITO T., DAI T., ASANO R.: The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumour cells. Oncol. Lett., 2013, 5, 1068-1074.
35. SAITO T., TAMURA D., NAKAMURA T., MAKITA Y., ARIYAMA H., KOMIYAMA K., YOSHIHARA T., ASANO R.: 4-Methylumbelliferone leads to growth arrest and apoptosis in canine mammary tumour cells. Oncol. Rep., 2013, 29, 335-342.
36. SCHNEIDER R., DORN C. R., TAYLOR D. O.: Factors influencing canine mammary cancer development and postsurgical survival. J. Natl Cancer Inst., 1969, 43, 1249-1261.
37. SIMON D., KNEBEL J. W., BAUMGÄRTNER W., AUFDERHEIDE M., MEYER-LINDENBERG A., NOLTE I.: In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumours obtained from dogs. Am. J. Vet. Res., 2001, 62, 1825-1830.
38. SIMON D., SCHOENROCK D., BAUMGÄRTNER W., NOLTE I.: Postoperative adjuvant treatment of invasive malignant mammary gland tumours in dogs with doxorubicin and docetaxel. J. Vet. Intern. Med., 2006, 20, 1184-1190.
39. SINGER J., WEICHSELBAUMER M., STOCKNER T., MECHTCHERIAKOVA D., SOBANOV Y., BAJNA E., WRBA F., HORVAT R., THALHAMMER J. G., WILLMANN M., JENSEN-JAROLIM E.: Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol. Immunol., 2012, 50, 200-209.
40. SINGER J., FAZEKAS J., WANG W., WEICHSELBAUMER M., MATZ M., MADER A., STEINFELLNER W., MEITZ S., MECHTCHERIAKOVA D., SOBANOV Y., WILLMANN M., STOCKNER T., SPILLNER E., KUNERT R., JENSEN-JAROLIM E.: Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol. Cancer Ther., 2014, 13, 1777-1790.
41. SLEECKX N., DE ROOSTER H., VELDHUIS KROEZE E. J. B., VAN GINNEKEN C., VAN BRANTEGEM L.: Canine mammary tumours, an overview. Reprod. Domestic Anim., 2011, 46, 1112-1131.
42. SONZOGNI-DESAUTELS K., KNAPP D. W., SARTIN E., DORÉ M.: Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours. Vet. Comp. Oncol., 2011, 9, 161-171.
43. SORENMO K. U., WORLEY D. R., GOLDSCHMIDT M. H.: Tumours of the mammary gland. In: S. J. WITHROW, D. M. VAIL, R. L. PAGE (éd): Withrow & MacEwen's Small Animal Clinical Oncology, 5th edn, Saunders/Elsevier Inc., St. Louis, Missouri, 2013, 538-556.
44. SURGERY FOR BREAST CANCER [Internet]: American Cancer Society, Atlanta, Georgia [updated 2014 Sept 25, cited 2015 Jul. 7]. Available from: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-surgery
45. TAVARES W. L., LAVALLE G. E., FIGUEIREDO M. S., SOUZA A. G., BERTAGNOLLI A. C., VIANA F. A., PAES P. R., CARNEIRO R. A., CAVALCANTI G. A., MELO M. M., CASSALI G. D.: Evaluation of adverse effects in tamoxifen exposed healthy female dogs. Acta Vet. Scand., 2010, 52, 67. DOI: 10.1186/1751-0147-52-67
46. THAMM D. H., ROSE B., KOW K., HUMBERT M., MANSFIELD C. D., MOUSSY A., HERMINE O., DUBREUIL P.: Masitinib as a chemosensitizer of canine tumour cell lines: A proof of concept study. Vet. J., 2012, 191, 131-134.
47. TRAN C. M., MOORE A. S., FRIMBERGER A. E.: Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy. Vet. Comp. Oncol., 2014, DOI: 10.1111/vco.12092
48. ÜSTÜN ALKAN F., ÜSTÜNER O., BAKIREL T., ÇINAR S., ERTEN G., DENIZ G.: The effects of piroxicam and deracoxib on canine mammary tumour cell line. The Scientific World J., 2012, Article ID 976740, 8 pages. Available from: http://dx.doi.org/10.1100/2012/976740
49. ÜSTÜN ALKAN F., BAKIRE T., ÛSTÜNER O., YARDIBI H.: In vitro effects of doxorubicin and deracoxib on oxidative-stress-related parameters in canine mammary carcinoma cells. Acta Vet. Hung., 2014, 62, 372-385.
50. WILSON H., CHADALAPAKA G., JUTOORU I., SHEPPARD S., PFENT C., SAFE S.: Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (sp) transcription factors, and sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells. J. Vet. Intern. Med., 2012, 26, 977-986.
51. YAMASHITA A., MARUO K., SUZUKI K., SHIROTA K., KOBAYASHI K., HIOKI K.: Experimental chemotherapy against canine mammary cancer xenograft in SCID mice and its prediction of clinical effect. J. Vet. Med. Sci., 2001, 63, 831-836.
52. YARDLEY D. A.: Taxanes in the elderly patient with metastatic breast cancer. Breast Cancer: Targets and Therapy, 2015, 7, 293-301.